zofenoprilat   Click here for help

GtoPdb Ligand ID: 6463

Approved drug PDB Ligand
zofenoprilat is an approved drug (FDA)
Compound class: Synthetic organic
Comment: Drug from metabolism of zofenopril prodrug. Note the PDB ligand structure is for a different target, not ACE
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 121.71
Molecular weight 325.08
XLogP 2.64
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES SCC(C(=O)N1CC(CC1C(=O)O)Sc1ccccc1)C
Isomeric SMILES SC[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)Sc1ccccc1)C
InChI InChI=1S/C15H19NO3S2/c1-10(9-20)14(17)16-8-12(7-13(16)15(18)19)21-11-5-3-2-4-6-11/h2-6,10,12-13,20H,7-9H2,1H3,(H,18,19)/t10-,12+,13+/m1/s1
InChI Key UQWLOWFDKAFKAP-WXHSDQCUSA-N
No information available.
Summary of Clinical Use Click here for help
Active form of the prodrug zofenopril which is used in the treatment of hypertension and coronary heart disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Angiotensin coverting enzyme inhibitor. Zofenoprilat competes with angiotensisn I for binding to ACE thereby inhibiting its enzymatic conversion to angiotensin II. Reduced levels of angiotensin II leads to reduced blood pressure. However, we have been unable to find molecular data for this drug at the human target, to substantiate its MMOA.